Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Transgene Will Present a Poster on Preclinical Data from a Novel Oncolytic Virus at SITC 2026Strasbourg, France, October 5, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster highlighting preclinical data with PoxSTG-EEV, a novel enveloped oncolytic virus designed for systemic delivery, at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. SITC 2026 will take place November 4 - 8, 2026, in Phoenix, Arizona (USA).
- Schall, Brown & Schwartz LLPAARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS LawSchall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aardvark Therapeutics, Inc. ("Aardvark" or "the Company") (NASDAQ: AARD) for violations of §§10(b) and 20(a)...
- The Rosen Law Firm PAROSEN, TRUSTED TRIAL COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...
- Celaid Therapeutics Inc.Celaid Therapeutics Completes Second Close of Series B Financing RoundShionogi & Co., Ltd. and Teikoku Ventures, Inc. Join the Round to Accelerate U.S. Clinical Trial Preparations for CLD-001 — Celaid Therapeutics Inc. (Head Office: Bunkyo-ku, Tokyo, Japan; President and CEO: Nobuyuki Arakawa; "Celaid") today announced the...
- AAVantgardeAAVantgarde Presents Encouraging Clinical Data from AAVB-081 and Preclinical Data Supporting AAVB-039 at EURetina 2026The company has presented updated data from the LUCE-1 Phase 1/2 study in Usher syndrome type 1B and preclinical data supporting the clinical translation of AAVB-039 in Stargardt disease
- CSLCSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseasesAlentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared — CSL and Alentis Therapeutics today announced they have entered into an exclusive global...
- The VIVA FoundationLate-Breaking Clinical Trial Results Announced at The VEINS 2026The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine through education and research, today announced results from the Late-Breaking Clinical Trials presented at The VEINS 2026 conference, held at...
- Vaxcyte, Inc.Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine CandidateVaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced it will host a webcast and conference call tomorrow, October 5, 2026 at 8:00 a.m. ET / 5:00 a.m. PT to present topline data from the OPUS-1 adult pivotal Phase 3 trial evaluating the safety, tolerability and immunogenicity of VAX-31, the Company’s 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD) and pneumococcal pneumonia.
- The Rosen Law Firm PAARS PHARMACEUTICALS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline.SO WHAT: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
- Proexpo Communications LimitedKexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in ChinaRecently, Kexing Biopharma (688136.SH) announced that its wholly owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing"), has received a Notice of Approval for Drug Clinical Trials from China's National Medical Products Administration (NMPA), authorizing the initiation of clinical trials of GB20, a proprietary investigational anti-TL1A monoclonal antibody for inflammatory bowel disease (IBD).Inflammatory bowel...
- The Rosen Law Firm PAAARDVARK DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action - AARDWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the "Class...
- Faruqi & Faruqi LLPSPRY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ARS Pharmaceuticals between March 9, 2026 and June 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]New York, New...